Navigation Links
Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Date:3/6/2008

December 31,

2007 2006 2005 2007

$ $ $ $

-------------------------------------------------------------------------

Revenue

Rights revenue - - - 310,000

-------------------------------------------------------------------------

- - - 310,000

-------------------------------------------------------------------------

Expenses

Research and

development 11,315,088 10,535,689 9,308,977 54,536,282

Operating 3,987,688 3,630,144 3,083,372 20,758,269

Stock based

compensation 539,156 403,550 64,104 4,704,805

Foreign

exchange loss 8,862 35,270 253,608 657,710

Amortization

- intellectual

property 962,427 874,043 786,459 4,999,261

Amortization

- capital assets 40,714 52,637 69,532 448,397

-------------------------------------------------------------------------

16,853,935 15,531,333 13,566,052 86,104,724

-------------------------------------------------------------------------

Loss before the

following 16,853,935 15,531,333 13,566,052 85,794,724

Interest income (1,211,744) (1,233,809) (783,456) (6,014,749)

Gain on sale of

BCY LifeSciences

Inc. - - (765) (299,403)

Loss on sale of

Transition

Therapeutics

Inc. - - - 2,156,685

---------------------------------------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
4. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
9. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
10. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
11. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , FREISING-WEIHENSTEPHAN, Germany , ... preclinical data for its proprietary PRS-110 Anticalin(R),compound, which targets ... in a xenograft mouse model. The results provide an,indication ... may,be of significant therapeutic value in treating cancer. A ...
... ... supplies irrigation management solutions. The company was approved for $250,000 for completion and commercialization ... plant is the sensor™.” , ... (Vocus) April 30, 2010 -- Smartfield, Inc. is ...
... DENVER , April 29 HEALTHeCAREERS Network , ... and career resources. , , ...   http://www.newscom.com/cgi-bin/prnh/20100204/FL49504LOGO-a ) , , ... The Society for Cardiovascular Angiography and Interventions (SCAI) recently joined the Network, ...
Cached Biology Technology:Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program 2$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2Healthcare Web site Expands Reach to Cardiology Professionals 2Healthcare Web site Expands Reach to Cardiology Professionals 3
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
(Date:4/17/2014)... novel method to help kidney stone sufferers ensure ... possible., Kidney stones represent a major medical problem ... untreated, apart from being particularly painful, they can ... many patients treated successfully, stone recurrence is also ... to diagnosis and treatment needs to be identified ...
(Date:4/17/2014)... University researchers have detected new early-warning signs of the ... could have far-reaching implications for the diagnosis and treatment ... 25 million Americans. , "We had not expected to ... early stages," said Ann Elsner, professor and associate dean ... of the study. "We set out to study the ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Dangerous disease often spreads faster than it takes to ... at Kansas State University have developed a test to ... Sanjeev Narayanan, assistant professor, and Greg Peterson, research microbiologist, ... use a device called a DNA spotted microarray to ...
... double-stranded DNA into the space of a typical chromosome, ... genetic material it contains. "It is like compacting ... Professor Emeritus in Physics at the University of Chicago. ... is showing that these and related organisms may have ...
... D.C. (August 21, 2008) The Aplastic Anemia ... patients that the U.S. Food & Drug Administration (FDA) ... data from the AZA-001 trial, which found that Vidaza ... (myelodysplastic syndromes) patients. Vidaza was also shown to delay ...
Cached Biology News:Rapid test for pathogens developed by K-State researchers 2Exploding chromosomes fuel research about evolution of genetic storage 2Exploding chromosomes fuel research about evolution of genetic storage 3
... This kit allows for quick and reproducible immunoprecipitation ... The system is more reproducible than regular IPs, ... protein A/G agarose without disrupting the agarose bed. ... and Release is reversible, and elution of the ...
... Polyclonal Antibody, Unconjugated ... a dilution of 1/100. IP: Use ... Use at an assay dependent dilution. ... tested in other applications. Optimal ...
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Using multicolor analysis in a modern flow ... cells that are differentially labeled with fluorescent ... dyes typically used for cell labeling are ... by a flow cytometers filters. Thus, the ...
Biology Products: